144 related articles for article (PubMed ID: 36913542)
21. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
[TBL] [Abstract][Full Text] [Related]
22. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
[TBL] [Abstract][Full Text] [Related]
23. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
Jhalani NB
Adv Ther; 2022 Aug; 39(8):3472-3487. PubMed ID: 35699903
[TBL] [Abstract][Full Text] [Related]
24. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Kashiwagi A; Shoji S; Onozawa S; Kosakai Y; Waratani M; Ito Y
J Diabetes Investig; 2022 Jul; 13(7):1175-1189. PubMed ID: 35243799
[TBL] [Abstract][Full Text] [Related]
25. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
27. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
[TBL] [Abstract][Full Text] [Related]
28. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
29. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
30. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence.
McEwan P; Bennett H; Khunti K; Wilding J; Edmonds C; Thuresson M; Wittbrodt E; Fenici P; Kosiborod M
Diabetes Obes Metab; 2020 Dec; 22(12):2364-2374. PubMed ID: 32744392
[TBL] [Abstract][Full Text] [Related]
31. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
32. Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database.
Kohsaka S; Kumamaru H; Nishimura S; Shoji S; Nakatani E; Ichihara N; Yamamoto H; Miyachi Y; Miyata H
J Diabetes Investig; 2021 Aug; 12(8):1452-1461. PubMed ID: 33345452
[TBL] [Abstract][Full Text] [Related]
33. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.
Champion M; Wills Avila G; Garcia AE; Álvarez Delgado FM; Valdez CA
J Prim Care Community Health; 2024; 15():21501319241231398. PubMed ID: 38353180
[TBL] [Abstract][Full Text] [Related]
34. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
[TBL] [Abstract][Full Text] [Related]
35. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
36. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
[TBL] [Abstract][Full Text] [Related]
37. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
[TBL] [Abstract][Full Text] [Related]
38. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chen WJ
Diabetologia; 2022 Dec; 65(12):2032-2043. PubMed ID: 35945333
[TBL] [Abstract][Full Text] [Related]
39. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
[TBL] [Abstract][Full Text] [Related]
40. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
